NanosiRNA Huntington's disease (Medesis Pharma)

N/A

Report date: 2024/03/04 17:50:32
NME

Base Information

Drug NameNanosiRNA Huntington's disease (Medesis Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interference
TargetsUpdating
Therapy Area/IndicationsHuntington Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMedesis Pharma Sa
China Registration ClassN/A

Develop Information

Active CompaniesMedesis Pharma Sa
Inactive CompaniesN/A
Active IndicationsHuntington Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A